Currently, several FDA-approved drugs exploit this strategy for the treatment of Duchenne muscular dystrophy (DMD), including Eteplirsen, Golodirsen, Casimersen, and Viltolarsen [21,22,23,24,52,53], designed to skip selected exons from the DMD transcript. Here, DMD is linked to Duchenne muscular dystrophy.